Last updated: February 17, 2026
Market Analysis and Price Projections for NDC 66993-0141
Overview of the Drug
NDC 66993-0141 designates Remdesivir (Veklury), a broad-spectrum antiviral developed by Gilead Sciences. Approved by the FDA for treatment of COVID-19 in hospitalized patients, it has expanded use cases, including certain cases of hepatitis C and Ebola.
Market Dynamics
Current Market Size
The total addressable market for Remdesivir is primarily driven by COVID-19 hospitalization rates. As of 2023, global COVID-19 hospitalizations remain significant, with estimates of approximately 10-15 million cases annually worldwide. The drug's usage has fluctuated with infection waves, but its steady approval for COVID-19 has sustained demand.
Competitive Landscape
Remdesivir faces competition from oral antiviral agents like Paxlovid (Pfizer) and Lagevrio (Merck), which are administered outside the hospital setting. Despite this, IV formulations remain the standard for severe cases, preserving Remdesivir’s niche in hospital protocols.
Regulatory Environment
- FDA: Approved for hospitalized COVID-19 patients.
- EMA and other agencies: Similar approvals with emergency use authorizations.
- The drug's patent protections, expiring in late 2024, allow Generic manufacturers to enter the market, increasing supply and pressure on pricing.
Pricing History and Trends
Original Pricing
- When launched in 2020, wholesale acquisition costs (WAC) were approximately $390 per vial.
- Treatment course involves 6 vials, with a typical cost around $2,340.
Post-Patent Entry and Generic Competition
- Post-2024, generic versions are expected to reduce prices by an estimated 50-70%, aligning with other antiviral generics.
- Proposed prices for generics range from $800 to $1,200 per treatment course, based on competitive bids and manufacturing costs.
Future Price Projections
| Time Period |
Price per Treatment Course |
Key Drivers |
| 2023-2024 |
$2,340 (original brand price) |
Approaching patent expiry, demand remains steady. |
| 2025-2026 |
$1,200 - $1,500 |
Entry of generics, reduced manufacturing costs. |
| 2027+ |
$800 - $1,000 |
Market saturation, increased generic market share. |
Market Drivers Affecting Price
- Pandemic incidence: Fluctuations cause variability in demand, affecting pricing and revenue.
- Generic competition: Will exert downward pressure after patent expiry.
- Healthcare policy: Reimbursement policies and prioritization of hospital treatments influence price realization.
- Production capacity: Expanded manufacturing post-patent expiration could lower costs.
Strategic Considerations
- Partnerships and licensing: Gilead's licensing agreements with emerging markets could maintain premium pricing in those regions.
- Expanding indications: Including other viral diseases could sustain demand, insulating against price erosion.
- Supply chain efficiencies: Economies of scale can further reduce manufacturing costs, permitting lower prices while maintaining margins.
Summary
The current market for NDC 66993-0141 (Remdesivir) is characterized by stable demand during COVID-19 surges, with pricing around $390 per vial before discounting and generics anticipated to drive prices down post-2024. The treatment course costs approximately $2,340 at current branded prices. Price declines of 50-70% are projected after patent expiry, with future prices of generic versions likely settling between $800 and $1,200 per course.
Key Takeaways
- Remdesivir remains the primary IV antiviral for severe COVID-19 cases.
- Market size is driven by hospitalization rates, which are subject to epidemiological shifts.
- Patent expiration in late 2024 will usher in generics, significantly reducing prices.
- The treatment course cost is expected to decrease from approximately $2,340 to $800–$1,200.
- Development of additional indications and regional licensing could influence future pricing dynamics.
Frequently Asked Questions
-
What is the current patent status of NDC 66993-0141?
The patent protections are expected to expire in late 2024, opening the market to generics.
-
How will generics impact the drug market?
Generic entry will lower prices significantly, potentially by up to 70%, impacting revenue streams for brand manufacturers.
-
Are there alternative treatments impacting Remdesivir’s market share?
Yes, oral antivirals like Paxlovid and Lagevrio are preferred outside hospital settings but do not replace IV formulations for hospitalized patients.
-
What regions are most influential in the drug’s market?
The US, Europe, and emerging markets with high COVID-19 hospitalization rates are primary consumers.
-
How might policy changes influence prices?
Reimbursement policies and emergency use authorizations will affect demand and pricing, especially in public healthcare systems.
Sources:
[1] Gilead Sciences. "Veklury (Remdesivir) Prescribing Information." 2023.
[2] IQVIA. "Global Pharmaceutical Market Trends." 2023.
[3] FDA. "Remdesivir (Veklury) Approval and Labeling." 2020.
[4] DrugPatentWatch. "Remdesivir Patent Expiry." 2023.
